TISSUE ENGINEERING AND CELL TRANSPLANTATION: U.S. MARKETS FOR ORGAN REGENERATION PRODUCTS

122 Pages | 13 Exhibits | 2010 Analysis | Forecasts Through 2019

OVERVIEW:
This new report from Medtech Insight analyzes the potential United States (U.S.) market for organ regeneration products. During the forecast period covered by this report, this market is projected to increase from approximately $15.3 billion in 2009 to an estimated $23.9 billion in the year 2019 (based on a potential patient caseload of 1.1 million).

The largest opportunities for organ regeneration lie in diseases/disorders of the bone marrow, kidneys, liver, pancreas, and small intestine. Market segments covered by this report include bioartificial kidneys and livers/liver regeneration products, bone marrow regeneration products, pancreas regeneration products, and small intestine replacement products. Various tissue engineering technologies including genes, scaffolds, stem cells, and xenotransplants are being researched for applications in organ regeneration.

This new report also provides a clinical overview of selected diseases/disorders that are amenable to treatment with tissue-engineered and cell transplantation products and includes the most up-to-date incidence and prevalence figures.

This report is the fifth in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. The final report in this series will provide an analysis of the U.S. market for tissue-engineered skin replacement and skin substitute products.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Clinical Applications for Organ Regeneration
	a. Bone Marrow Disease
	b. Diabetes
	c. Intestinal Disorders
	d. Kidney Disease
	e. Liver Disease
ii. Tissue Engineering Technologies
	a. Biomaterials
	b. Cell Culture Technology
	c. Stem Cell Technology
	d. Immunoisolation Technology
iii. Technologies Under Development for Organ Regeneration
	a. Bone Marrow Regeneration Technologies
	b. Intestine Regeneration Technologies
	c. Kidney Regeneration Technologies
	d. Liver Regeneration Technologies
	e. Pancreas Regeneration Technologies
	f. Bioartificial Organ Technologies
iv. Market Analysis
v. Methodology

Exhibit ES-1: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019

1. CLINICAL OVERVIEW OF TISSUE ENGINEERING APPLICATIONS FOR ORGAN REGENERATION

1.1 Disease Incidence
	1.1.1 Bone Marrow Disease
		1.1.1.1 Aplastic Anemia
		1.1.1.2 Leukemia and Lymphoma
	1.1.2 Diabetes
	1.1.3 Intestinal Disorders
		1.1.3.1 Intestinal Pseudo-Obstruction
		1.1.3.2 Microvillus Inclusion Disease
		1.1.3.3 Short Bowel Syndrome
	1.1.4 Kidney Disease
	1.1.5 Liver Disease
1.2 Existing Therapies
	1.2.1 Ex Vivo Systems
		1.2.1.1 Kidney Dialysis Systems
	1.2.2 Organ Transplantation
		1.2.2.1 Bone Marrow Transplantation
		1.2.2.2 Kidney Transplantation
		1.2.2.3 Liver Transplantation
			1.2.2.3.1 Split Cadaveric Livers
			1.2.2.3.2 Liver Segments from Living Donors
		1.2.2.4 Pancreas Transplantation
		1.2.2.5 Intestinal Transplantation

Exhibit 1-1: Incidence and Prevalence of Major Organ Diseases/Disorders
Exhibit 1-2: Organ Transplantation, by Type, Procedure Volumes, and Waiting List
Exhibit 1-3: Average Estimated First-Year Billed Charges, Per Transplant

2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES

2.1 Biomaterials
	2.1.1 Synthetic Biomaterials
	2.1.2 Biologically Derived Biomaterials
		2.1.2.1 Collagen
		2.1.2.2 Xenogeneic Tissue
	2.1.3 Hybrid Biomaterials
	2.1.4 Genetically Engineered Biomaterials
		2.1.4.1 Deoxyribonucleic Acid Transfection Vectors
		2.1.4.2 Genetically Manipulated Cells
		2.1.4.3 Three-Dimensional Polymer Technology
		2.1.4.4 Transgenics
		2.1.4.5 Fibroblasts
		2.1.4.6 Immortalized Neural Stem Cells
		2.1.4.7 Gene-Activated Matrices
	2.1.5 Scaffolds
	2.1.6 Vascular Grafts
2.2 Cell Culture Technology
	2.2.1 Bioreactors
		2.2.1.1 Flatbed Perfusion Systems
		2.2.1.2 Hollow Fiber Bioreactor Systems
		2.2.1.3 Cell Suspension Systems
		2.2.1.4 Disposable Bioreactors
2.3 Stem Cell Technology
	2.3.1 Cell Extraction and Expansion
	2.3.2 Bioreactors
2.4 Immunoisolation Technology
	2.4.1 Chimeric Immunity
	2.4.2 Cell Encapsulation Technology

Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering
Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering
Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies

3. TISSUE ENGINEERING AND CELL TRANSPLANTATION: U.S. MARKETS FOR ORGAN REGENERATION PRODUCTS

3.1 Emerging Technologies and Products
	3.1.1 Genes
	3.1.2 Scaffolds
	3.1.3 Stem Cells
	3.1.4 Xenotransplants
	3.1.5 Bone Marrow
		3.1.5.1 Gamida Cell
		3.1.5.2 Osiris Therapeutics
		3.1.5.3 SituGen
		3.1.5.4 University of Texas M.D. Anderson Cancer Center and the ViaCord Research Institute/ViaCord/PerkinElmer
	3.1.6 Intestine
	3.1.7 Kidney
		3.1.7.1 Tengion
	3.1.8 Liver
		3.1.8.1 Cytonet
		3.1.8.2 StemCells
		3.1.8.3 Vesta Therapeutics
	3.1.9 Pancreas
		3.1.9.1 BioTime
		3.1.9.2 Cerco Medical
		3.1.9.3 Geron
		3.1.9.4 Juvenile Diabetes Research Foundation
		3.1.9.5 Osiris Therapeutics
		3.1.9.6 ViaCyte
		3.1.9.7 StemCells
		3.1.9.8 TheraCyte
		3.1.9.9 Transition Therapeutics
		3.1.9.10 ViaCord/PerkinElmer
		3.1.9.11 Vitro Biopharma/Vitro Diagnostics
3.2 Artificial Organ Technologies
	3.2.1 Bioartificial Kidney
	3.2.2 Bioartificial Liver
		3.2.2.1 Excorp Medical
		3.2.2.2 Gambro
		3.2.2.3 HepaLife Technologies
		3.2.2.4 Hep-Art Medical Devices
		3.2.2.5 Hybrid Organ
		3.2.2.6 Vital Therapies
		3.2.2.7 Xenogenics/MultiCell Technologies
	3.2.3 Artificial Pancreas
		3.2.3.1 Juvenile Diabetes Research Foundation
		3.2.3.2 Medtronic
3.3 Market Analysis
	3.3.1 Market Drivers
	3.3.2 Market Limiters
3.4 Competitors

Exhibit 3-1: 2010, Selected Emerging Treatment Products for Liver Failure
Exhibit 3-2: 2010, Selected Emerging Treatment Products for Pancreatic Failure
Exhibit 3-3: 2010, Selected Bioartificial and Artificial Organ Products
Exhibit 3-4: Medtronic's STAR 3 Study Results
Exhibit 3-5: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019
Exhibit 3-6: Organ Regeneration Technologies, by Indication, 2009 and 2019

4. COMPANY PROFILES

4.1 BioTime, Inc.
4.2 Cerco Medical LLC
4.3 Cytonet GmbH & Co. KG
4.4 Geron Corporation
4.5 Osiris Therapeutics, Inc.
4.6 PerkinElmer, Inc.
4.7 StemCells, Inc.
4.8 Tengion, Inc.
4.9 Vesta Therapeutics, Inc.
4.10 ViaCyte, Inc.

APPENDIX: COMPANY LISTING


COMPANIES COVERED:

  1. BioTime, Inc.
  2. Cerco Medical LLC
  3. Cytonet GmbH & Co. KG
  4. Geron Corporation
  5. Osiris Therapeutics, Inc.
  6. PerkinElmer, Inc.
  7. StemCells, Inc.
  8. Tengion, Inc.
  9. Vesta Therapeutics, Inc.
  10. ViaCyte, Inc.
Contact Us

Need help finding medtech research? Let us help you!